FDA Panel Recommends Loosening Peptide Restrictions
A Food and Drug Administration (FDA) advisory panel recommended relaxing restrictions on several peptides despite government scientists warning about thin evidence on their safety and effectiveness. Over recent years, wellness influencers and celebrities have popularized peptides, promoting their antiaging, anti-inflammatory, and longevity benefits. The panel’s guidance could permit certain pharmacies to supply substances like BPC-157, KPV, and TB-500 via prescription.
The FDA’s Pharmacy Compounding Advisory Committee, in a close 8-6 vote with one abstention, suggested adding these peptides to the agency’s 503A bulk drug substances list. This recommendation does not equate to FDA approval but may allow compounding pharmacies and physicians to produce them under specified conditions. The FDA typically follows such panel guidance, although it is not mandatory.
Health Secretary and Experts’ Views on Peptides
Health Secretary Robert F. Kennedy Jr., identifying himself as a “big fan” of peptides, has pledged to overturn FDA restrictions introduced under the Biden administration. Reportedly, he included new panel members with peptide-related business ties.
Some experts express significant concerns about the panel’s recommendation. Dr. Pieter Cohen of Harvard University argues that there is insufficient evidence regarding the safety of these peptides in humans. He also doubts claims regarding their muscle healing, longevity, or antiaging benefits. “The safety of these compounds is unknown in humans,” Cohen noted, warning of potential risks like cancer or heart disease.
Understanding Peptides
Peptides are short amino acid chains, foundational to proteins, naturally occuring in the body where they regulate processes like inflammation, appetite, and tissue repair. BPC-157, derived from human gastric juice amino acids, is noted for antioxidant and wound-healing benefits in animals, but lacks comprehensive human studies.
KPV, a pituitary-derived three-amino-acid peptide, is studied for its potential in reducing inflammation, primarily in cell and animal models. Research emphasizes that findings do not directly translate to human biology effects.
TB-500, often linked to thymosin beta-4 found in human cells, relates to cardiac, stroke, and wound repair in preclinical studies. Experts caution that significant human studies focus on thymosin beta-4 rather than TB-500 sold in wellness contexts.
Why Peptides Are Popular
Peptides have gained traction in wellness and “biohacking” communities. They are touted for muscle recovery, injury healing, antiaging, and more, though many claimed uses lack FDA-approved backing. Claims often stem from cell or animal models suggesting potential for stress reduction and tissue regeneration.
Market Research Future estimates the peptide market at $43.12 billion in 2024, with potential growth to $91.79 billion by 2035. North America currently leads the market, with rapid growth in Asia-Pacific territories.
Interest is reflected in U.S. Google searches, with “how to get peptides” showing a 1,019% surge between March 2025 and February 2026. The query “are peptides safe” saw 27,100 searches in February 2026, highlighting growing safety concerns.
Safety Concerns Surrounding Peptides
FDA scientists highlight limited evidence of BPC-157, KPV, and TB-500’s safety or effectiveness, noting potential risks like triggering immune responses with injectable versions. The advisory panel plans to vote on additional peptides like emideltide for opioid withdrawal, semax for migraines, and epitalon for insomnia.
Emideltide is most researched among them, with studies dating back to 1981. Still, benefits remain inconclusive, and the FDA has not identified adequate nonclinical toxicity studies for clinical safety considerations.
The Experimental Drug Review Process
Dr. Cohen described the proceedings as an “inversion” of the typical drug review process, where experts evaluate safety and efficacy evidence to determine if benefits surpass risks. He remarked that such experimental drugs, lacking efficacy and safety evidence, should not be presented to an FDA panel. He concluded that the peptide decisions contradict the principle that the FDA approves drugs only after thorough clinical trials.
For additional insights, Newsweek editors Sam Stevenson and Shakeema Edwards contributed to this report.